Skip to main content
Clinical Trials/NCT04319887
NCT04319887
Completed
N/A

A Prospective, Multicenter, Single-arm Study Examining ECAP-controlled, Closed-loop Stimulation With the Evoke Spinal Cord Stimulator (SCS) System to Treat Patients With Chronic Pain of the Trunk and/or Limbs

Saluda Medical Pty Ltd22 sites in 1 country300 target enrollmentOctober 29, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Chronic Pain
Sponsor
Saluda Medical Pty Ltd
Enrollment
300
Locations
22
Primary Endpoint
Evoked Compound Action Potentials (ECAPs) as Measured by the Evoke SCS System
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of this study is to evaluate neurophysiological measures and clinical outcomes of the Evoke System to treat trunk and/or limb pain in a real-world population.

Registry
clinicaltrials.gov
Start Date
October 29, 2020
End Date
December 28, 2023
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Saluda Medical Pty Ltd
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Subject has chronic intractable pain of the trunk and/or limbs.
  • Subject is willing and capable of giving informed consent and able to comply with study-related requirements, procedures, and visits.

Exclusion Criteria

  • Subject is unable to operate the system.
  • Subject is an unsuitable surgical candidate.
  • Subject has a condition currently requiring or likely to require the use of diathermy.
  • Subject has another implantable stimulator such as demand type pacemakers or cardioverter defibrillator.
  • Subject is \<18 years old.
  • Subject is pregnant or nursing.
  • Subject is allergic, or has shown hypersensitivity, to any materials of the neurostimulation system which come in contact with the body.
  • Subject is being treated with electroconvulsive therapy (ECT) or transcranial magnetic stimulation (rTMS).

Outcomes

Primary Outcomes

Evoked Compound Action Potentials (ECAPs) as Measured by the Evoke SCS System

Time Frame: 12-months post-implant

Dose ratio is determined by the estimated current (mA) at the median ECAP level divided by the current (mA) at the ECAP threshold. The dose ratio allows for both the individualization of a patient's neural dose and comparison across patients, using their ECAP threshold and unique dose response. This metric normalizes for distance between the electrode and the spinal cord and the distances between the stimulation and recording electrodes. The dose ratio reflects the amount of dorsal column activation elicited by stimulation with respect to threshold levels. For example, if the dose is at ECAP threshold, this value will be 1. If the dose is 30% higher than ECAP threshold, this value will be 1.3.

Study Sites (22)

Loading locations...

Similar Trials